Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 883-896 , October 2008

Epstein–Barr virus in autoimmune diseases

  • Éric Toussirot, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author: Tel.: +33 3 81 66 82 41; Fax: +33 3 81 66 86 86.

References 

  1. James JA, Harley JB, Scofield RH. Role of viruses in systemic lupus erythematosus and Sjögren syndrome. Current Opinion in Rheumatology. 2001;13:370–376
  2. James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Current Opinion in Rheumatology. 2006;18:462–467
  3. Vaughan JH. The Epstein-Barr virus in autoimmunity. Springer Seminars in Immunopathology. 1995;17:203–230
  4. Lotz M, Roudier J. Epstein-Barr virus and rheumatoid arthritis. Cellular and molecular aspects. Rheumatology International. 1989;9:147–152
  5. Kanegane H, Wakiguchi H, Kanegane C, et al. Viral interleukin-10 in chronic active Epstein-Barr virus infection. The Journal of Infectious Diseases. 1997;176:254–257
  6. Harley JB, Harley ITW, Guthridge JM, et al. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus. 2006;15:768–777
  7. McClain MT, Harley B, James JA. The role of Epstein-Barr virus in systemic lupus erythematosus. Frontiers in Bioscience. 2001;6:137–147
  8. Poole BD, Scofield RH, Harley JB, et al. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39:63–70
  9. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. The Journal of Clinical Investigation. 1997;100:3019–3026
  10. James JA, Neas BN, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis and Rheumatism. 2001;44:1122–1146
  11. Lu JJY, Chen DY, Hsich CW, et al. Association of Epstein-Barr virus infection with systemic lupus eythematosus in Taiwan. Lupus. 2007;16:168–175
  12. Parks CG, Cooper GS, Hudson LL, et al. Association of Epstein-Barr virus with systemic lupus erythematosus. Effect modification by race, age and cytotoxic lymphocyte - associated antigen 4 genotype. Arthritis and Rheumatism. 2005;52:1148–1159
  13. Petersen J, Rhodes G, Roudier J, et al. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism. 1990;33:993–1000
  14. Yu SF, Wu HC, Tsai WC, et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Medical Microbiology and Immunology. 2005;194:15–120
  15. Gross AJ, Hochberg D, Rand W, et al. EBV and systemic lupus erythematosus: a new perspective. Journal of Immunology. 2005;174:6599–6607
  16. Moon UY, Park SJ, Oh ST, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Research & Therapy. 2004;6:R295–R302
  17. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. Journal of Immunology. 2004;172:1287–1294
  18. Tsokos G, Magrath IT, Balow JE. Epstein-Barr virus infection induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. Journal of Immunology. 1983;131:1797–1804
  19. Berner BR, Tary-Lehman M, Yonkers NL, et al. Phenotypic and functional analysis of EBV specific memory CD8 cells in SLE. Cellular Immunology. 2005;235:29–38
  20. Vaughan JH, Nguyen MD, Valbrecht JR, et al. Epstein-Barr virus induced autoimmune responses. The Journal of Clinical Investigation. 1995;95:1316–1327
  21. James JA, Harley JB. Lupus humoral autoimmunity after short peptide immunization. Annals of the New York Academy of Sciences. 1997;815:124–127
  22. Riemekasten G, Marell J, Trebelijahr G, et al. A novel epitope on the C terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. The Journal of Clinical Investigation. 1998;102:754–763
  23. Mc Clain MT, Heinlen LD, Dennis GJ, et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nature Medicine. 2005;11:85–89
  24. Verdolini R, Bugatti R, Giangacomi M, et al. Systemic lupus eythematosus induced by Epstein-Barr virus infection. The British Journal of Dermatology. 2002;146:877–881
  25. Kasapcopur O, Ergul Y, Kutlug S, et al. Systemic lupus erythematosus due to Epstein-Barr virus or Epstein-Barr virus infection provocating acute exacerbation of systemic lupus erythematosus?. Clinical Rheumatology. 2006;26:765–767
  26. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine. 2007 Oct;74(5):418–426
  27. Klatt T, Ouyang Q, Flad T, et al. Expansion of peripheral CD8 + CD28 - T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. The Journal of Rheumatology. 2005;32:239–251
  28. Fox RI, Luppi M, Pisa P, et al. Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis. The Journal of Rheumatology. 1992;19(Suppl. 32):18–24
  29. Van Eden W, Hogervorst J, Hensen E, et al. A cartilage mimicking epitope on a 65 kD mycobacterial heat shock protein: adjuvant arthritis as amodel for human rheumatoid arthritis. Current Topics in Microbiology and Immunology. 1989;145:27–43
  30. Baboonian C, Venables PJW, Willaim DG, et al. Cross reaction of antibodies to a glycine alanine repeat sequence of Epstein-Barr virus nuclear antigen 1 with collagen, cytokeratin and actin. Annals of the Rheumatic Diseases. 1991;50:772–775
  31. Roudier J, Petersen J, Rhodes G, et al. Susceptibility to rheumatoid arthritis maps to a T cell epitope shared by HLA-Dw4 DR beta 1 chain and the Epstein-Barr virus glycoprotein gp110. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:5104–5108
  32. Toussirot E, Wendling D, Tiberghien P, et al. Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2000;59:533–538
  33. Scotet E, David-Ameline J, Peyrat MA, et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. The Journal of Experimental Medicine. 1996;184:1791–1800
  34. Toussirot E, Wendling D, Luka J, et al. Increased frequency of T cells specific for Epstein-Barr virus glycoprotein gp110 in the synovial fluid of patients with rheumatoid arthritis. Arthritis Research & Therapy. 2003;5:S25
  35. Saal JG, Krimmel M, Steidle M, et al. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis and Rheumatism. 1999;42:1485–1496
  36. Balandraud N, Meynard JB, Auger I, et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis. Accurate quantification using real-time polymerase chain reaction. Arthritis and Rheumatism. 2003;48:1223–1228
  37. Anzilotti C, Merlini G, Pratesi F, et al. Antibodies to viral citrullinated peptide in rheumatoid arthritis. The Journal of Rheumatology. 2006;33:647–651
  38. Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:733–741
  39. Wittingham S, McNeilage J, Mackay IR. Primary Sjögren's syndrome after infectious mononucleosis. Annals of Internal Medicine. 1985;102:490–493
  40. Fox RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus associated antigens and DNA in salivary gland biopsies from patients with Sjögren's syndrome. Journal of Immunology. 1886;137:3162–3168
  41. Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome. The American Journal of Medicine. 1991;90:286–294
  42. Wen S, Shimizu N, Yoshimaya H, et al. Association of Epstein-Barr virus with Sjögren's syndrome: differential EBV expression between epithelial cells and lymphocytes in salivay glands. The American Journal of Pathology. 1996;149:1511–1517
  43. Venables PJW, Teo CG, Baboonian C, et al. Persistence of Epstein-Barr virus in salivary gland biopsies from healthy individuals and patients with Sjögren's syndrome. Clinical and Experimental Immunology. 1989;75:359–364
  44. Navone R, Lunardi C, Gerli R, et al. Identification of tear lipocalin as a novel autoantigen target in Sjögren's syndrome. Journal of Autoimmunity. 2005;25:229–234
  45. Nagata Y, Inoue H, Yamada K, et al. Activation of Epstein-Barr virus by saliva from Sjögren's syndrome patients. Immunology. 2004;111:223–229
  46. Okano M. The evolving therapeutic approaches for Epstein-Barr virus infection in immunocompetent and immunocompromized individuals. Current Drug Targets. Immune, Endocrine and Metabolic Diseases. 2003;3:137–142
  47. Okano M, Gross TG. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromized patients. Expert Review of Anti-Infective Therapy. 2007;5:403–413
  48. Shoda H, Nakazaki K, Izutsu K, et al. Epstein-Barr virus associated mononucleosis caused by weekly low dose methotrexate therapy in a rheumatoid arthritis patient. Scandinavian Journal of Rheumatology. 2006;35:152–163
  49. Dawson TM, Starkebaum G, Wood BL, et al. Epstein-Barr virus, methotrexate and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series. The Journal of Rheumatology. 2001;28:47–53
  50. Mariette X. Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis. Leukemia & Lymphoma. 1999;33:93–99
  51. Royen B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B - cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766–775
  52. Hirose Y, Sugai S, Masaki Y, et al. Epstein-Barr virus study in malignant lymphoma in Sjögren's syndrome. International Journal of Hematology. 1999;69:174–179
  53. Xu Y, Wiermick PH. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus. 2001;10:841–850
  54. Löfström B, Baklin C, Sundström C, et al. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Annals of the Rheumatic Diseases. 2007;66:1627–1632
  55. Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non -Hodgkin lymphoma in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2005;64:1507–1509
  56. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis and Rheumatism. 2005;52:1481–1490
  57. Kojima M, Nakamura S, Futamura N, et al. Malignant lymphoma in patients with rheumatic diseases other than Sjögrens' syndrome: a review of the Japanese literature. Japanese Journal of Clinical Oncology. 1997;27:84–90
  58. Balandraud N, Guis S, Meynard JB, et al. Long term treatment with methotrexate or TNF inhibitors does not increase Epstein Barr virus load in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2007;57:762–767
  59. Balandraud N, Roudier J, Roudier C. What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?. Seminars in Arthritis and Rheumatism. 2005;34(Suppl. 1):31–33

PII: S1521-6942(08)00104-6

doi: 10.1016/j.berh.2008.09.007

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 883-896 , October 2008

Article Tools